CAJ | 학술논문

目的：观察丹红对脑梗塞再灌注大鼠运动功能改善的治疗作用。方法 SD大鼠制备大脑中动脉阻塞模型，再灌注24 h后随机分为对照组、丹红高剂量、丹红低剂量组及维脑路通组。对照组生理盐水腹腔注射，丹红高、低剂量组据大鼠体质量给予丹红注射液14.4 mg/kg和3.6 mg/kg腹腔注射，维脑路通组以0.04 g/kg腹腔注射给药。计算脑梗死灶面积，行横木行走实验，双前肢抓握力量检测。结果各组大鼠在24 h 和3 d 可见对照组梗塞面积最大，与其他各组比较，差异有统计学意义(P<0.05)。大鼠3 d时横木行走实验，对照组、维脑路通组、丹红高、低剂量组得分分别为：(1.30±0.91)分、(3.78±1.72)分、(4.18±2.05)分、(4.63±2.45)分，用药各组与对照组相比，有统计学差异(P<0.05)。药物组与对照组大鼠双前肢肌力有统计学差异(P<0.05)。结论丹红可明显提高大鼠运动功能恢复，且与维脑路通作用相当。
목적：관찰단홍대뇌경새재관주대서운동공능개선적치료작용。방법 SD대서제비대뇌중동맥조새모형，재관주24 h후수궤분위대조조、단홍고제량、단홍저제량조급유뇌로통조。대조조생리염수복강주사，단홍고、저제량조거대서체질량급여단홍주사액14.4 mg/kg화3.6 mg/kg복강주사，유뇌로통조이0.04 g/kg복강주사급약。계산뇌경사조면적，행횡목행주실험，쌍전지조악역량검측。결과각조대서재24 h 화3 d 가견대조조경새면적최대，여기타각조비교，차이유통계학의의(P<0.05)。대서3 d시횡목행주실험，대조조、유뇌로통조、단홍고、저제량조득분분별위：(1.30±0.91)분、(3.78±1.72)분、(4.18±2.05)분、(4.63±2.45)분，용약각조여대조조상비，유통계학차이(P<0.05)。약물조여대조조대서쌍전지기력유통계학차이(P<0.05)。결론단홍가명현제고대서운동공능회복，차여유뇌로통작용상당。
Objective To investigate Danhong in improving the movement function of reperfused rat after stroke. Methods Rats to make middle cerebral artery occlusion model,after 24 hours of reperfusion were divided into control group,high dose and low dose of Danhong groups and Venorruton group randomly. Rats in Control group were injected saline. High and low dose group were injected DanHong according to their weight,high dose as 14. 4 mg/kg,low dose as 3. 6 mg/kg. Venorruton group were injected Venorruton as 0. 04 g/kg. The infarcted square of rat brain was measured,the rats were tested with walking wood bar and two fore limb grasp strength. Results Rat infarcted squre in 24 hours and 3 days,control groups is the biggest,compared with others,there are statistically difference(P<0. 05). Score in each group of walking wood bar in 3rd days are (1. 30 ± 0. 91),(3. 78 ± 1. 72),(4. 18 ± 2. 05),(4. 63 ± 2. 45). Compared between control and other druge groups,there are statistically differnec(P<0. 05). There are statistically differences between control and other groups in two fore limb grasp testing(P<0. 05). Conclusion Danhong has the same effect which can improve the movement function to stroke rat as Venorruton.